← Leaderboards
Stephen Edward Braun
Harvard Medical School
$2,480,034
Attributed
$2,713,784
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $602.4K · FY2008–20$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$2,713,784 · 5
By mechanism
R33$1,517,469 · 1
R21$936,779 · 2
P51$259,536 · 2
Top collaborators
- Amitinder Kaur2 shared
Most similar at Harvard Medical School
Same institution · by research overlap
- Simon Young$4,502,912
- Ruth Serra Moreno$2,720,350
- Jeremy Phillip Kamil$4,200,209
- John J Mekalanos$34,471,043
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroViralInfectionCellsIn VivoCellular TransductionVirusT-LymphocyteVectorMacaca MulattaInhibitor/AntagonistChimeric ProteinsAdoptive TransferAntiretroviral TherapyChimeric Antigen ReceptorRetroviral VectorHiv-1BiodistributionGenerationsExtracellularGene TherapyCd28 GeneLife Cycle StagesAntigen Binding
Grant awards (10)
Genetically Modified NKT Cells to Target Viral Reservoirs$170,000
R21 · FY2020 · AI
Genetically Modified NKT Cells to Target Viral Reservoirs$297,500
R21 · FY2019 · AI
Modified CMV-specific T cells to Target HIV$498,745
R33 · FY2018 · AI · contact PI
Modified CMV-specific T cells to Target HIV$502,933
R33 · FY2017 · AI · contact PI
Modified CMV-specific T cells to Target HIV$515,791
R33 · FY2016 · AI · contact PI
Modified CMV-specific T cells to Target HIV$86,572
R21 · FY2016 · AI · contact PI
Modified CMV-specific T cells to Target HIV$184,186
R21 · FY2015 · AI · contact PI
Modified CMV-specific T cells to Target HIV$198,521
R21 · FY2014 · AI · contact PI
STEM CELL GENE THERAPY FOR AIDS USING AN ANTI-SIV ENVELOPE ANTISENSE MOLECULE$129,768
P51 · FY2008 · RR · contact PI
SURVIVAL OF THE FITTEST: CHALLENGING TRANSDUCED CELLS WITH HIV-1 REPLICATION$129,768
P51 · FY2008 · RR · contact PI